MedTrace Logo

A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg

NCT00726414 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2010-02-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate capsules following a single, oral dose in healthy volunteers under fasting and fed conditions.

Conditions

  • Healthy

Interventions

DRUG

Quinine Sulfate 2 x 324 mg Capsules

Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.

DRUG

Quinine Sulfate 2 x 324 mg Capsules

Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.

Sponsors & Collaborators

  • Mutual Pharmaceutical Company, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2005-12-31
Completion
2005-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00726414 on ClinicalTrials.gov